Company also announces that the IMPACT-1 clinical trial is underway with open-label results expected in the coming months NEW YORK, Sept. 21, 2023 /PRNewswire/ — Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.